The Key Diabetic Foot Ulcers Companies in the market include - Amniox (TissueTech), Topadur Pharma, Cynata Therapeutics, Transwell Biotech, Aposcience, Ilya Pharma ...
Microbion Phase 2 study shows favorable safety and early efficacy data, with 46.7% of patients treated achieving complete wound closure. As the first compound in a new drug class, pravibismane ...
(MENAFN- EIN Presswire) Microbion Phase 2 study shows favorable safety and early efficacy data, with 46.7% of patients treated achieving complete wound closure. As the first compound in a new drug ...
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). The trial ...
In the trial, subjects with moderately infected chronic diabetic foot ulcers received either the topical pravibismane plus standard of care (SoC) or SoC alone. Credit: CGN089/Shutterstock. Microbion ...
-- Study achieves primary endpoint, demonstrating safety and tolerability of 12-week treatment regimen with high-concentration of topical pravibismane -- High patient compliance observed with at-home ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results